BioCentury
ARTICLE | Clinical News

GS-504 nucleotide analog: Began Phase I/II trial

June 6, 1994 7:00 AM UTC

Gilead Sciences Inc. (GILD), Foster City, Calif. Product: GS-504 nucleotide analog Indication: Bone marrow transplant recipients at risk for cytomegalovirus (CMV) infection Status: Began Phase I/II t...